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Objectives. To examine circadian changes in the sympathovagal
balance, the activity of the renin-angiotensin system and hemo-
static variables in patients with stable coronary artery disease,
and the effects of beta-adrenoceptor blockade and angiotensin-
converting enzyme inhibition.
Background. Sympathovagal balance and key components of
the fibrinolytic system show circadian variability. The effects of
beta-adrenergic blocking agents and angiotensin-converting en-
zyme inhibitors on these autonomic and hemostatic rhythms are
not well defined.
Methods. Twenty patients with coronary artery disease under-
went 24-h Holter monitoring for heart rate variability and blood
sampling (6 hourly for 24 hours) after three consecutive treatment
phases, (firstly with placebo, then bisoprolol, and finally
quinapril). The effects on sympathovagal balance, hemostatic
variables and the renin-angiotensin system activity were mea-
sured.
Results. The fibrinolytic capacity showed marked circadian
variation at the end of the placebo phase (p 5 0.002), plasminogen
activator inhibitor-1 (PAI-1) activity peaking at 06.00 AM when
tissue plasminogen activator (tPA) activity was at its nadir.
Sympathovagal balance showed a sharp increase at approximately
the same time but plasma renin activity did not rise until later in
the day. Inspection of the 24-h profiles suggested that bisoprolol
reduced sympathovagal balance and the morning peak of PAI-1
activity and antigen, with a small increase in tPA activity,
although these changes were not significant. Quinapril produced
a substantial rise in renin (p 5 0.01) but did not significantly
affect either PAI-1 or tPA. Sympathovagal balance was unaffected
by quinapril.
Conclusions. In patients with stable coronary artery disease,
angiotensin-converting enzyme inhibition with quinapril does not
affect either sympathovagal balance or the endogenous fibrinolytic
system. Our data suggest that the sympathoadrenal system may
modify fibrinolytic activity, judged by the response to beta-
adrenoreceptor blockade with bisoprolol.
(J Am Coll Cardiol 1998;32:1962–8)
©1998 by the American College of Cardiology
The circadian rhythm of acute myocardial infarction is well
documented. A significant excess of patients present during the
second quarter of the day. Mechanisms remain unclear al-
though considerable evidence points to a role for the sympa-
thetic nervous system; thus, circadian variability of plasma
catecholamines has long been recognized (1), and in patients
with stable angina, the morning peak in ambulatory ischemia
coincides with a peak in sympathetic activity (2,3). It is now
apparent that the circadian rhythm of myocardial infarction is
attenuated or abolished in patients taking beta-blockers (4,5),
and in other groups with deranged autonomic function (6,7). A
plausible mechanism accounting for these observations is that
myocardial ischemia and plaque events are provoked by the
heart rate and blood pressure responses to sympathetic stim-
ulation which peaks during the second quarter of the day.
Other mechanisms may also contribute to the circadian
rhythm of myocardial infarction. Key components of the
endogenous fibrinolytic system show circadian variability (8–
13), peak and trough plasma activities of plasminogen activator
inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA)
combining to provide a relatively prothrombotic state in the
morning (14) when the risk of thrombotic coronary occlusion is
greatest. Factors responsible for regulating these fibrinolytic
products of the vascular endothelium are unclear although
there is some evidence for involvement of the renin-
angiotensin system (RAS); thus, when RAS activation is
simulated by angiotensin II infusion (15), or occurs patho-
physiologically during myocardial infarction (16), plasma levels
of PAI-1 increase, a response prevented by angiotensin-
converting enzyme inhibition.
If the sympathetic and renin angiotensin systems interact to
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heighten the risk of infarction during the second quarter of the
day, intervention with specific inhibitors would be expected to
exert a protective effect by favorably influencing the hemody-
namic and fibrinolytic environment. In the present study, this
hypothesis was tested by examining circadian changes in
sympathovagal balance, RAS activity and circulating hemo-
static variables in patients with stable coronary artery disease,
with particular reference to the effects of beta-adrenoceptor
blockade with bisoprolol and angiotensin-converting enzyme
inhibition with quinapril.
Methods
Patients. Twenty patients aged 40–70 years with angio-
graphically confirmed coronary artery disease were recruited
(Table 1). All were either asymptomatic or had mild stable
angina (Canadian class I-II), with well-preserved left ventric-
ular function (ejection fraction . 50%). Exclusion criteria
included diabetes, hypertension and current treatment with
angiotensin-converting enzyme inhibitors. The study was ap-
proved by the East London and City Health Authority Re-
search Ethics Committee, and all patients gave written in-
formed consent. All patients completed the placebo run-in
phase of the trial, but three did not complete the first
treatment period with bisoprolol (personal reasons [n 5 1],
intercurrent illness [n 5 1], bronchospasm [n 5 1]) and three
did not complete the second treatment period with quinapril
(personal reasons [n 5 2], intercurrent illness [n 5 1]); thus,
data for both treatment phases are for 17 patients.
Study protocol. This was a single blind study. Patients first
underwent a placebo run-in phase for four weeks and this was
followed by two consecutive treatment periods first with biso-
prolol and then with quinapril (each for four weeks). Bisopro-
lol was chosen for its b1 cardioselective properties and
quinapril for its high tissue angiotensin-converting enzyme
binding capacity. Before the placebo run-in phase, aspirin and
all vasoactive drugs except short-acting nitrates were stopped
and not reintroduced until after the end of the study. Smokers
were asked to refrain from smoking for 24 h before Holter
monitoring until after the final blood sample on each admis-
sion.
Placebo run-in phase. Patients received one capsule of
placebo in the morning, which was increased to two capsules at
the end of the first week. After four weeks on placebo, the
patients underwent 24-h ambulatory Holter monitoring using a
Marquette Series 8000 recorder. This was followed by admis-
sion to a hospital at 9 AM. Blood was collected at 12 PM, 6 PM,
12 AM, and 6 AM for analysis of renin levels, tPA antigen and
activity, PAI-1 antigen and activity, fibrinogen, von Willebrand
factor (vWF), beta-thromboglobulin (bTG) and platelet factor
4 (PF4).
First treatment period (Bisoprolol). At the end of the pla-
cebo run-in phase, placebo capsules were stopped and biso-
prolol (10 mg daily) was substituted, with a dose increment to
20 mg daily after one week if the resting heart rate re-
mained . 60 beats per minute. After four weeks on bisoprolol,
Holter monitoring and blood sampling were repeated as
described above.
Second treatment period (Quinapril). At the end of the
bisoprolol treatment period, quinapril (10 mg daily) was
substituted, increasing to 20 mg daily after one week if systolic
blood pressure remained . 100 mmHg. After four weeks on
quinapril, Holter monitoring and blood sampling were re-
peated as described above.
Heart rate variability. All Holter recordings were analyzed
by a single physician blinded to the identity and treatment
phase of the patient. The recordings were analyzed for spectral
and nonspectral measures of heart rate variability with
Marquette heart rate variability software. The measures calcu-
lated were: amplitude of low (0.04 – 0.15 Hz) and high
(0.15–0.40 Hz) frequency spectral analysis for each hour and
24 hour means, proportion of adjacent electrocardiographic R
intervals (RR) intervals more than 50 ms different (pNN50),
root-mean square of difference of successive RR intervals
(rMSSD), mean of all 5-minute standard deviations or RR
intervals (SD), standard deviation of 5-minute mean RR
intervals (SDANN), and the standard deviation of all RR
intervals (SDNN).
Blood sampling and analysis. All samples were taken from
the antecubital fossa after 3 h bed rest through a 21 gauge
needle, using a tourniquet only briefly to gain venous access;
the first 2 ml of blood were discarded. Blood was collected for
renin measurement into 5-ml tubes containing sodium EDTA
Abbreviations and Acronyms
bTG 5 beta-thromboglobulin
PAI-1 5 plasminogen activator inhibitor-1
PF4 5 platelet factor 4
RAS 5 renin-angiotensin system
tPA 5 tissue plasminogen activator
vWF 5 von Willebrand factor
Table 1. Characteristics of the 20 Study Patients
Men n 5 18
Age 57.3 6 7.9
Previous Q wave MI n 5 8
Smokers n 5 7
Body mass index (kg m22) 28.4 6 5.0
Urea (mol l21) 5.74 6 1.49
Creatinine (mmol l21) 113 6 11.6
Hemoglobin (g dl21) 14.5 6 1.22
Total cholesterol (mmol l21) 5.33 6 0.84
Triglycerides (mmol l21) 1.83 6 0.64
Treatment
Bisoprolol
20 mg n 5 9
10 mg n 5 8
Quinapril
20 mg n 5 16
10 mg n 5 1
Numbers are mean 6 standard deviation unless otherwise stated.
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(Vacutainer, Becton Dickinson, Oxford, UK), fibrinogen and
tPA antigen and activity into 5-ml tubes containing sodium
citrate (Vacutainer, Becton Dickinson), and bTG, PF4 and
PAI-1 antigen and activity into tubes containing theophylline,
adenosine and prostaglandin PGE1 (Diatubes, Becton Dick-
inson). The latter samples were centrifuged for 30 min at
2,500 g and 4°C. Only the mid-sample of the platelet-free
plasma was decanted. The other samples were centrifuged at
2,500 g for 10 min at 4°C. Samples were collected into
precooled tubes in iced water, and were kept cold until
freezing at 240°C. Analyses were performed in a single batch
within 9 months of initial sampling.
All assays were performed using commercially available kits
on paired samples. Renin activity was measured by immuno-
radiometric assay (Nichols Institute Diagnostics, Geneva, Swit-
zerland). Tissue plasminogen activator and PAI-1 antigen were
measured by enzyme-linked immunosorbent assay (ELISA;
Technoclone, Vienna, Austria) and tPA and PAI-1 activity
were measured by a two-step indirect enzymatic assay (Tech-
noclone, Vienna, Austria). Beta-thromboglobulin was mea-
sured by ELISA (Asserchrom bTG, Diagnostica Stago,
Asnieres-sur-Seine, France) but samples were discarded if
there was evidence of in vitro platelet activation (ratio of
bTG:PF4 , 2 [17]). von Willebrand factor was measured by
ELISA (Shield Diagnostics, Dundee, UK) and fibrinogen by
the modified Clauss method (Immuno, Heidelberg, Germany).
To test for sample deterioration, log linear regression
analysis was performed for all hematological variables against
the time which had elapsed since their collection. No time-
dependent changes in measured values were detected.
Statistical analysis. Data are presented as mean 6 stan-
dard deviation unless otherwise stated. Tests of circadian
variation and comparisons of daily means and time profiles
during the three treatment phases were based on repeated
measures (two-way) analysis of variance, and subsequent ad-
justments for multiple testing were made using the Bonferroni
method (18). Logarithmic transformation was performed on
four variables (renin, PAI-1 antigen, bTG and PF4) to nor-
malize their skewed distribution. Quoted p-values correspond
to comparison of all three treatment phases; p-values of 0.05 or
less were regarded as significant.
Results
Efficacy of treatment. Compliance rates, assessed by tablet
counting, were: placebo 99%, bisoprolol 97%, quinapril 97%.
Bisoprolol reduced heart rate compared with placebo (57 6 11
versus 76 6 7.6 beats per minute, p , 0.0001), and systolic and
diastolic blood pressure measurements (114 6 8.8 versus
124 6 10.7 mmHg, p 5 0.02; 67 6 7.1 versus 76 6 8.9 mmHg,
p 5 0.001). Quinapril produced small reductions in systolic and
diastolic blood pressures (117 6 17.3 versus 124 6 10.7 mmHg,
p 5 0.16; 70 6 11 versus 76 6 8.9 mmHg, p 5 0.05). The heart
rate at the end of the quinapril treatment phase was no
different than during the placebo phase (79 6 11 beats per
minute) but substantial elevation of 24-h mean plasma renin
levels occurred (106 6 182 versus 21.6 6 17.4 mU ml21, p ,
0.0001).
Hematological factors. Fibrinolytic system. All four key
components of the endogenous fibrinolytic system (Fig. 1)
showed circadian variation at the end of the placebo run-in
phase (p 5 0.002 in each case). Treatment with quinapril did
not significantly affect these circadian rhythms. The effect of
bisoprolol also failed to reach statistical significance after
correction for multiple comparisons; however, observation of
the data in Fig. 1 suggests some attenuation of the morning
peak of PAI-1 activity compared with placebo and a small
increase in tPA activity throughout the 24-h period.
Platelet activity. Beta thromboglobulin showed no signifi-
cant circadian variation after the placebo run-in phase (Fig. 2).
Treatment with quinapril and bisoprolol tended to reduce
plasma levels over the 24 h, although this effect was not
statistically significant.
von Willebrand factor and fibrinogen. These showed no
significant circadian variation and were unaffected by bisopro-
lol or quinapril (Table 2).
Autonomic function. The ratio of the low to high frequency
spectral components of heart rate variability showed significant
circadian variation at the end of the placebo run-in phase (p 5
0.002) with a sharp rise starting at around 5 AM and a nadir at
midnight. Observation of the data in Fig. 3 shows evidence of
a difference between treatment phases. Bisoprolol diminished
the LF:HF ratio throughout the 24-h period and effectively
abolished the morning increase. Again, however, this response
to beta-blockade is not statistically significant following adjust-
ment for multiple comparisons; nevertheless, bisoprolol did
cause significant increases in many of the nonspectral mea-
sures of heart rate variability (Table 3). Quinapril had no
appreciable influence on heart rate variability.
Renin-angiotensin system. There was again evidence of
difference between the three treatment phases in mean level
(p 5 0.01) and diurnal pattern (p 5 0.002) of plasma renin
levels (Fig. 4). Placebo and bisoprolol phases were very similar,
but angiotensin-converting enzyme inhibition led to a substan-
tial increase in daily mean level, peaking at 12 PM.
Discussion
This study has shown that in stable patients with coronary
artery disease, angiotensin-converting enzyme inhibition with
quinapril affects neither the circadian rhythm of fibrinolytic
activity nor the morning surge of sympathetic activity. Beta-
adrenoceptor blockade with bisoprolol, on the other hand,
reduces sympathetic activity and may also favorably influence
the fibrinolytic system by reducing the relatively prothrombotic
state that occurs around 6 AM when the risk of myocardial
infarction is greatest. Quinapril and bisoprolol tends to reduce
platelet activity as reflected by beta-thromboglobulin.
Circadian rhythms of sympathovagal balance and fibrino-
lytic activity. Spectral analysis of heart rate variability follow-
ing the placebo run-in period confirmed a significant circadian
variation of sympathovagal balance (19) which increased
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sharply in the early morning (3). Key components of the
fibrinolytic system showed a similar pattern, PAI-1 activity,
PAI-1 antigen and tPA antigen (which binds to PAI-1) peaking
at 6 AM when tPA activity was at its nadir, resulting in a
relatively prothrombotic state at a time when the risk of
myocardial infarction is greatest. Because pathogenic mecha-
nisms of myocardial infarction involve plaque rupture and
thrombosis (events influenced importantly by blood pressure
and endogenous fibrinolytic state), it is possible to speculate
that the circadian changes in sympathovagal balance and the
fibrinolytic system which we and others have demonstrated
account, at least in part, for the circadian rhythm of acute
myocardial infarction.
Effects of beta-blockade on circadian rhythms. Attenua-
tion or absence of the circadian rhythm of acute myocardial
infarction in patients taking beta-blockers has been reported
by several investigators (4,5), suggesting that reductions in
sympathetic activity might protect against plaque events during
the period of heightened risk. Observation of Fig. 3 shows that
bisoprolol reduced sympathovagal balance throughout the day,
effectively abolishing the morning surge in activity. Bisoprolol
may also have modified fibrinolytic activity, and there was a
tendency for the morning surge in PAI-1 activity to be reduced
while mean tPA activity increased throughout the 24-h period.
These changes were small and lacked statistical significance,
particularly with adjustment for multiple comparisons, al-
though there is some debate about whether statistical infer-
ence is improved by Bonferroni adjustments (20–22); however,
the flat contour of the PAI-1 activity curve after four weeks on
bisoprolol contrasted strongly with the placebo curve, suggest-
ing that there may indeed have been a response to beta-
adrenoreceptor blockade.
In contrast to PAI-1, the circadian rhythm of tPA activity
Figure 2. Variation in b-TG over 24 h and the effect of treatment with
beta-blocker (bisoprolol) and angiotensin-converting enzyme inhibitor
(quinapril). Points represent mean values; figures are the standard
deviation for each data point. P1 5 placebo; BB 5 beta-blocker;
ACEI 5 angiotensin-converting enzyme inhibitor.
Figure 1. Circadian variation of PAI-1
and tPA antigens and activities and the
effect of treatment with beta-blocker
(bisoprolol) and angiotensin-converting
enzyme inhibitor (quinapril). Points rep-
resent mean values; figures are the stan-
dard deviation for each data point. P1 5
placebo; BB 5 beta-blocker; ACEI 5
angiotensin-converting enzyme inhibitor.
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was unaffected by bisoprolol, perhaps reflecting the fact that
tPA is produced almost exclusively by the vascular endothe-
lium while PAI-1 has, in addition, many nonendothelial
sources (23) which may be more susceptible to the effects of
beta-blockade; nevertheless, the effects of bisoprolol on fi-
brinolytic activity were potentially favorable and reduction in
the morning surge of PAI-1 activity would be expected to
reduce the risk of thrombotic coronary occlusion and comple-
ment the hemodynamic responses to beta-blockade in modify-
ing the circadian rhythm of acute myocardial infarction.
Mechanisms whereby beta-blockade with bisoprolol might
affect the fibrinolytic system are unclear and must remain
speculative until factors regulating the endothelial production
of PAI-1 and tPA are better understood. Certainly, there is no
evidence for a direct effect of the sympathetic nervous system
on endothelial function although indirect effects on the endo-
thelial production of vasoactive substances, mediated by vari-
ations in blood flow and sheer stress, are well documented
(24,25). The morning rise in sympathovagal balance and PAI-1
activity were approximately simultaneous. Because both were
attenuated by bisoprolol, indirect effects of sympathetic activity
on the vascular endothelium provide a potential mechanism
for the circadian rhythm of PAI-1 activity and for the effects of
bisoprolol.
Effects of angiotensin-converting enzyme inhibition. At the
end of the placebo run-in phase, circadian changes in plasma
renin levels showed a strikingly different pattern from the
changes in fibrinolytic activity; thus, plasma renin peaked at
midday when PAI-1 and tPA activities were both relatively low.
The phase delay between cycles of renin release and fibrino-
lytic activity must cast doubt on the importance of the RAS in
regulating endothelial production of PAI-1 and tPA under
basal conditions, doubt that is amplified by our finding that
angiotensin-converting enzyme inhibition with quinapril, suffi-
cient to increase plasma renin levels by over 450%, had no
palpable effect on circadian rhythms or plasma activities of
PAI-1 and tPA. While this finding appears to contradict
previous experimental and clinical studies (16,26,27), it is
almost certainly attributable to the fact that ours were stable
patients without significant RAS activation, in contrast to
previous studies in which the RAS was activated at the time of
angiotensin-converting enzyme inhibition; thus, Hamdan et al.
(27) reported that RAS activation in the balloon-injured rat
aorta induced PAI-1 mRNA expression, a response suppressed
by captopril, while others have reported that RAS activation in
patients with myocardial infarction increased PAI-1 and tPA
antigen levels, responses that are also suppressed by
angiotensin-converting enzyme inhibition (16,26). Importantly,
in one of these myocardial infarction studies (16), the effects of
angiotensin-converting enzyme inhibition in a normal control
group was reported. In this group, PAI-1 and tPA antigen
levels were similar to the baseline data in our own patients and
were unaffected by angiotensin-converting enzyme inhibition.
It can be concluded, therefore, that when the RAS is activated,
it provides a potent stimulus for endothelial production of
PAI-1 (presumably mediated by angiotensin II), but under
basal conditions, other factors which may include the sympa-
thetic system, play a more important role in driving the
circadian rhythms of the endogenous fibrinolytic system. While
modifying these rhythms may contribute to the protective
effects of beta-blockade in stable patients with coronary artery
disease, the potential benefits of angiotensin-converting en-
zyme inhibition, currently under clinical investigation (28), are
more plausibly attributable to direct effects on the endothelial
production of nitric oxide and other components of the
atherogenic process (29).
Figure 3. Twenty-four hour variation of low frequency to high fre-
quency ratio (LF:HF) at baseline (placebo) and after treatment with
beta-blocker (bisoprolol) and angiotensin-converting enzyme inhibitor
(quinapril). Points represent mean values; figures are the standard
deviation for each data point. P1 5 placebo; BB 5 beta-blocker;
ACEI 5 angiotensin-converting enzyme inhibitor.
Table 2. von Willebrand Factor and Fibrinogen Levels at Baseline (Placebo) and After Treatment with Bisoprolol and Quinapril According to
the Time of Day
Placebo Bisoprolol Quinapril
12 AM 6 AM 12 PM 6 PM 12 AM 6 AM 12 PM 6 PM 12 AM 6 AM 12 PM 6 PM
von Willebrand Factor
(IU ml21)
109
(34.7)
98.3
(36.4)
108
(54.3)
105
(38.4)
123
(41.9)
102
(30.4)
101
(23.9)
104
(28.3)
115
(48.8)
110
(39.1)
110
(46.4)
111
(35.7)
Fibrinogen (mg dl21) 304
(89.3)
307
(73.0)
307
(72.5)
316
(71.4)
302
(95.5)
330
(74.2)
320
(90.0)
304
(74.9)
332
(81.7)
335
(66.0)
314
(60.2)
314
(84.1)
Figures in parentheses represent standard deviations.
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Effects of angiotensin-converting enzyme inhibition and
beta-blockade on platelet function. Angiotensin-converting
enzyme inhibitors and beta-blockers may also have useful
antiplatelet activity, judging by the small reductions in bTG
that followed treatment with quinapril and bisoprolol. Human
platelets possess angiotensin II and beta-adrenergic receptors
(28). Previous investigators have also reported inhibition of
platelet activity by angiotensin-converting enzyme inhibitors
(30,31) and less consistently by beta-blockers (32–35). Cer-
tainly, any antiplatelet effects of quinapril and bisoprolol would
be potentially beneficial in patients with coronary artery dis-
ease by protecting against thrombosis in the event of plaque
rupture. It is possible to speculate from our data that combi-
nation therapy might have useful additive effects given the
different mechanisms of action of these drugs. Other compo-
nents of the coagulation process measured in this study
included fibrinogen and von Willebrand factor, neither of
which were affected by angiotensin-converting enzyme inhibi-
tion or beta-blockade.
Conclusions. No evidence was found of a regulatory role
for the RAS in the endothelial production of PAI-1 or tPA
under basal conditions in patients with coronary artery disease;
however, this does not discount a role under conditions of RAS
activation. Our data suggest that the sympathoadrenal system
may influence fibrinolytic activity judging by responses to
beta-adrenoreceptor blockade with bisoprolol which tends to
reduce the relatively prothrombotic state that occurs in the
early morning. Bisoprolol also reduces sympathoadrenal activ-
ity with predictable hemodynamic consequences. These com-
bined hematological and hemodynamic responses to bisoprolol
may account, at least in part, for the protective effects of
beta-blockers, particularly in the early morning when the risk
of infarction is greatest.
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